VDI Technologies s.r.o., a Czech Republic-based medical device company developing cardiac ventricular dyssynchrony detection technology for more optimal pacemaker placement, announced the closing of Series A financing. Cardion s.r.o, a high-quality medtech company, leads the investment.
The new funding will enable VDI Technologies to finish the product development of the VDI UHF-ECG and to seek the certification of this breakthrough device in the United States and European Union countries. VDI will also further its imaging platform research with this financing.
"VDI's UHF-ECG platform will have a transformative impact on a range of pacemaker implantation procedures, including Conductive System Pacing, CRT, and leadless implants," said its CEO, Miroslav Navratil M.D. "All of us at VDI are excited to have someone with Cardion's EP market expertise as the lead investor."
"After successfully spinning off this technology from institutional research last year, we are thrilled to accelerate our pipeline development strategic efforts to boost traditional ECG applications with a tool that provides increased clinical sensitivity and specificity," said Pavel Jurak, Ph.D., Founder, CTO, of VDI. "Traction among fellow researchers is phenomenal, and we are excited to double down on our research reach and development efforts for pacemaker placement."
Pacing-induced cardio-myopathy resulting from suboptimal electrode placement has been recognized as a clinical challenge yet to be overcome. Electrophysiologists need a real-time, easy-to-operate, and easy-to-read tool that helps them assess if heartbeats are synchronous or dyssynchronous and increase the success rate of implant procedures. About 500k pacemakers are implanted annually between the U.S. and EU countries that would benefit from accurate ventricular dyssynchrony imaging.
With this additional financing, VDI is developing a tool that will be easy to implement and fully up to the task.